Immersive cardiac training tech gaining ground in high-stakes procedures

Tern plc

Fundamental XR is emerging as a key player in the shift toward immersive clinical training, offering a multimodal platform designed specifically for intracardiac interventions. Instead of relying on flat-screen visuals or isolated device simulations, this system merges real-world imaging modalities, including ultrasound, CT, fluoroscopy and 3D reconstructions, into a single virtual or mixed reality environment.

This matters because traditional training models are struggling to keep up with the demands of structural heart procedures. These interventions are becoming more intricate, with tighter tolerances and rising expectations around safety and efficiency. Platforms like Fundamental XR offer hospitals and manufacturers a tool to accelerate operator readiness, reduce avoidable errors, and improve procedural consistency, all of which are directly relevant to long-term value creation in this space.

What differentiates this model is its integration of full procedural context. Trainees don’t just learn isolated movements — they simulate the entire sequence of an intracardiac case, complete with real-time feedback from multimodal imaging. That creates a more realistic environment to develop the subtle spatial and tactile judgment needed for safe catheter navigation and device deployment. It also shortens the learning curve for new devices, which is increasingly important as manufacturers push for faster adoption cycles.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Talking Medicines targets a growing data need around GLP-1 treatment journeys

Talking Medicines is using GLP-1 discontinuation conversations to show how DrugVoice can help pharmaceutical companies track changing patient needs across the treatment journey.

Device Authority adopts usage-based pricing to support KeyScaler expansion

Device Authority has moved KeyScaler to usage-based pricing, aiming to reduce licensing friction and support broader adoption of its machine identity security platform.

Talking Medicines targets growing demand for GLP-1 patient intelligence

Talking Medicines is using GLP-1 patient conversations to show how behavioural data can help pharmaceutical companies understand changing treatment expectations and engagement.

Talking Medicines builds its AI strategy around specialist life sciences intelligence

Talking Medicines is positioning specialist healthcare intelligence as the core layer that gives agentic AI useful context in life sciences.

Device Authority targets cyber resilience opportunity at TechWorks Summit 2026

Device Authority will focus on continuous IoT and OT compliance, AI and quantum risk at TechWorks Summit 2026 as it strengthens its position in connected-device security.

Talking Medicines builds a more defensible AI model for life sciences

Talking Medicines is combining proprietary healthcare intelligence, AI agents and orchestration to build a more specialised AI platform for life sciences.

Search